BridgeBio Pharma Inc (NASDAQ:BBIO)’s traded shares stood at 0.66 million during the latest session, with the company’s beta value hitting 1.09. At the last check today, the stock’s price was $33.90, to imply a decrease of -0.03% or -$0.01 in intraday trading. The BBIO share’s 52-week high remains $39.47, putting it -16.43% down since that peak but still an impressive 36.22% since price per share fell to its 52-week low of $21.62. The company has a valuation of $6.45B, with an average of 2.65 million shares in intraday trading volume over the past 10 days and average of 2.90 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for BridgeBio Pharma Inc (BBIO), translating to a mean rating of 1.39. Of 9 analyst(s) looking at the stock, 0 analyst(s) give BBIO a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 9 recommend it as a Buy.
BridgeBio Pharma Inc (NASDAQ:BBIO) trade information
After registering a -0.03% downside in the latest session, BridgeBio Pharma Inc (BBIO) has traded red over the past five days. The 5-day price performance for the stock is 2.82%, and -7.89% over 30 days. With these gigs, the year-to-date price performance is 23.54%. Short interest in BridgeBio Pharma Inc (NASDAQ:BBIO) saw shorts transact 22.16 million shares and set a 6.64 days time to cover.
The extremes give us $45 and $46 for target low and target high price respectively. As such, BBIO has been trading -35.69% off suggested target high and -32.74% from its likely low.
BridgeBio Pharma Inc (BBIO) estimates and forecasts
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -3.04% for the past 5-year period. While 2025 is set for a -31.09% return in earnings, projections for the next 5 years are at 45.40% annually.
BBIO Dividends
BridgeBio Pharma Inc has its next earnings report out on 2025-Feb-19. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
BridgeBio Pharma Inc (NASDAQ:BBIO)’s Major holders
BridgeBio Pharma Inc insiders hold 5.41% of total outstanding shares, with institutional holders owning 91.10% of the shares at 96.31% float percentage. In total, 91.10% institutions holds shares in the company, led by KOHLBERG KRAVIS ROBERTS & CO. L.P. As of 2024-06-30, the company held over 31.06 million shares (or 16.5582% of shares), all amounting to roughly $786.77 million.
The next major institution holding the largest number of shares is VIKING GLOBAL INVESTORS LP with 25.12 million shares, or about 13.3917% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $636.31 million.
We also have Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund as the top two Mutual Funds with the largest holdings of the BridgeBio Pharma Inc (BBIO) shares. Going by data provided on Dec 31, 2024, Vanguard Total Stock Market Index Fund holds roughly 4.82 shares. This is just over 2.54% of the total shares, with a market valuation of $162.52 million. Data from the same date shows that the other fund manager holds a little less at 3.85, or 2.02% of the shares, all valued at about 129.71 million.
